Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash & Equivalents: 2018-2019

Historic Cash & Equivalents for DiaMedica Therapeutics (DMAC) over the last 2 years, with Sep 2019 value amounting to $4.7 million.

  • DiaMedica Therapeutics' Cash & Equivalents rose 21.63% to $4.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $4.7 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of $16.8 million for FY2018, which is N/A change from last year.
  • DiaMedica Therapeutics' Cash & Equivalents amounted to $4.7 million in Q3 2019, which was up 59.41% from $3.0 million recorded in Q2 2019.
  • In the past 5 years, DiaMedica Therapeutics' Cash & Equivalents ranged from a high of $16.8 million in Q4 2018 and a low of $2.8 million during Q1 2019.
  • Moreover, its 2-year median value for Cash & Equivalents was $4.7 million (2019), whereas its average is $6.2 million.
  • Examining YoY changes over the last 5 years, DiaMedica Therapeutics' Cash & Equivalents showed a top increase of 21.63% in 2019 and a maximum decrease of 58.88% in 2019.
  • Quarterly analysis of 2 years shows DiaMedica Therapeutics' Cash & Equivalents stood at $16.8 million in 2018, then grew by 21.63% to $4.7 million in 2019.
  • Its last three reported values are $4.7 million in Q3 2019, $3.0 million for Q2 2019, and $2.8 million during Q1 2019.